Inhibitors of human immunodeficiency virus replication

A compound of Formula I, or a pharmaceutically acceptable salt thereof:

• wherein:
• R0, R1, and R2 are each independently selected from hydrogen, Cl, F, —OMe, —CN, or —CH3 with the proviso that substituents Cl, —OMe, and —CH3 may not be used more than twice and substituent —CN may not be used more than once;
• Q is selected from:
• G2 is one of the following:
• wherein the benzene ring may be further substituted up to two times with fluorine and up to two times with chlorine with the proviso that no more than three substituents directly connected to the benzene ring are a halogen and no more than two substituents directly connected to the benzene ring are a chloride;
• G3 and G4 are independently selected from hydrogen, methyl, fluoro, chloro, or OC1-C2 alkyl with the proviso that at least one of G3 and G4 must be hydrogen;
• G5 is hydrogen, methyl, fluoro, chloro, OC1-C3 alkyl, cyano, —CH2OH, or —SO2(C1-C3 alkyl);
• G6 is hydrogen, methyl, fluoro, chloro, or OC1-C3 alkyl;
• G7 is hydrogen, methyl, fluoro, chloro, OC1-C3 alkyl, or COOH;
• G8 is hydrogen, C1-C4 alkyl, fluoro, chloro, OC1-C3 alkyl, COOH, —CN, —CH2OH, or —SO2(C1-C3 alkyl)
• G9 is hydrogen, C1-C4 alkyl, fluoro, chloro, OC1-C3 alkyl, COOH, CO-morpholine, C(CH3)2CH2OH, or —SO2-morpholine wherein C1-C4 alkyl is optionally substituted with 1-3 fluorines;
• R3 is hydrogen, Cl, or F;
• R4 is hydrogen, C1-C3 alkyl, or cyclopropyl wherein C1-C3 alkyl is optionally substituted with 1-3 fluorines and cyclopropyl is optionally substituted with 1-2 fluorines.
• R5 is C1-C3 alkyl or C3-C4 cycloalkyl;
• W is selected from:
• wherein R6 and R7 are independently selected from methyl optionally substituted with 1 to 3 fluorines.